Aimed Bio introduced its brain-centered platform by participating in ‘BIO KOREA 5 (Bio Korea 10)’, which opened on May 12th (Wednesday) and was held at COEX in Seoul for 3 days until May 2023th (Friday).
AimedBio is a company that develops new antibodies and ADCs specializing in brain diseases using big data and AI, and is currently developing pipelines for multiple brain tumors and neurodegenerative diseases.
In addition, various R&D programs are being developed through cooperation with domestic and foreign partners, including AMB302 and AMB018, which are supported by the Korea Developmental New Drug Foundation (KDDF). Last April, the American Association for Cancer Research (AACR) announced three preclinical results and precision medicine research results for AMB4/GQ302.
Regarding the brain-centered platform introduced at this exhibition, Aimed Bio said, “From the beginning to the end of drug development, there is a big data platform, antibody-drug conjugate (ADC) platform, brain-blood barrier (BBB) penetration platform, brain immune regulation platform, and “We maximize the effectiveness of brain treatments by utilizing five element technologies in combination, including the patient-derived model (PDC/PDX) platform,” he explained.
In addition, he said that by working with many clinical advisory committee members working directly in the field of patient treatment, he has established an optimal environment for the development of treatments for brain diseases by quickly identifying unmet medical needs in the field.
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th anniversary this year, was hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. BIO KOREA, which has been striving to improve the global status and sustainable growth of the Korean health industry since 2006, is solidifying its position as Korea’s representative biohealth international convention with the participation of world-class scholars and business experts every year. BIO KOREA 2023, in collaboration with companies related to the health industry such as domestic and foreign bio, pharmaceuticals, medical devices, cosmetics, and food, as well as interested companies and institutions such as consulting, academia, and related organizations, will be held through various programs such as conferences, business partnering, exhibitions, and investment fairs. It goes on.
→ Go to the BIO KOREA 2023 news special page
